Max Robotics — Global Service Robot Directory + US Certification

About

Satoshi Ishitoya is a leading figure in urologic oncology, with a focused expertise in optimizing surgical outcomes for prostate cancer patients. His research centers on the critical intersection of perioperative management and advanced surgical techniques, particularly robot-assisted radical prostatectomy. Ishitoya’s major contribution lies in clarifying the safety profile of antithrombotic therapy in this high-risk population. His landmark 2024 cohort study, which has already garnered 7 citations, systematically assessed the effects of thienopyridine-class antiplatelets—including ticlopidine, clopidogrel, and prasugrel—on bleeding complications following robotic surgery. By leveraging a comprehensive national database, this work provides essential, evidence-based guidance for surgeons navigating the delicate balance between thrombotic risk and hemorrhagic complications. This study is notable for its direct clinical impact, offering a framework for safer surgical planning. Ishitoya’s research is instrumental in advancing the precision and safety of minimally invasive urologic procedures, making him a key voice for clinicians and researchers dedicated to improving patient outcomes in prostate cancer care.